NAD+ injections and IVs: what the hype gets wrong

What did @nursedoza actually say?

The core claim here is that NAD+ IVs physically travel through your body toward damaged tissue, and that sensations like nausea, tingling, or muscle fatigue felt during the infusion are evidence of "real-time repair." The creator tells a patient's story: a man with a history of rotator cuff surgery felt shoulder tingling during a NAD+ IV, and the creator's interpretation was that the NAD+ was "going there and repairing it right now." They also describe NAD+ as "a B vitamin" that declines with age and helps produce energy. Some of that framing is in the right ballpark. The interpretation of what tingling means is not.

Does the science back this up?

No, not in the way the video presents it. NAD+ is a real coenzyme with legitimate research behind it, but the idea that infused NAD+ selectively migrates toward injured tissue and produces felt sensations as a sign of targeted repair is not supported by published evidence. The tingling and nausea commonly reported during NAD+ infusions are well-documented, but researchers attribute them to prostaglandin release and smooth muscle effects, not tissue-directed repair signals. A 2023 review by Mehmel et al. in Nutrients summarized that intravenous NAD+ does raise circulating NAD+ levels and may support cellular metabolism, but the mechanisms are systemic, not targeted. Studies on NAD+ precursors like NMN and NR (Yoshino et al., 2021, Science) show metabolic effects, not localized tissue homing. The "feeling" during infusion is a pharmacological side effect, not a repair readout.

What did they get wrong (or right)?

Credit where it's due: NAD+ does decline with age, and this is well-established (Verdin, 2015, Science). IV administration does raise plasma NAD+ levels acutely. The side effects the creator describes, including nausea, tingling, and chest tightness, are real and commonly reported. That part is accurate clinical observation.

What's wrong is the causal story built around those sensations. Saying NAD+ is "going exactly where you need it the most" and repairing tissue "in real time" treats a nonspecific physiological response as targeted diagnostic feedback. It isn't. The shoulder tingling in a post-surgical patient is more plausibly explained by referred sensation, infusion-rate effects on peripheral nerves, or simple coincidence. There is no published mechanism by which intravenous NAD+ homes to a previously injured joint. Presenting that interpretation to a patient as fact is a meaningful clinical overstep.

• Accurate: NAD+ declines with age
• Accurate: IV infusions cause tingling and nausea in many patients
• Inaccurate: Those sensations indicate targeted tissue repair
• Inaccurate: NAD+ "goes where it needs the most" in any directed, detectable way

What should you actually know?

NAD+ therapy is an active area of research, not a proven treatment for musculoskeletal injury. If you are considering a NAD+ IV, the sensations during infusion are a known side effect of infusion rate, not a compass pointing at damaged tissue. Slowing the infusion typically reduces them, which is exactly what happens in clinical settings. The fact that symptoms resolve when the drip slows confirms they are rate-dependent pharmacological effects, not repair signals switching off.

The broader issue is that symptom-as-diagnosis storytelling, where a patient feels something and a provider assigns a repair narrative to it, is not clinical evidence. It may feel compelling in the moment. It does not constitute a mechanism. If you are seeking NAD+ therapy for recovery or energy, discuss it with a licensed provider who can explain what the evidence actually supports, and what it does not, before you build expectations around how it should feel.